Journals / Retina-Vitreus / 2008 / Cilt: 16 - Sayı: 3

Yaşa bağlı makula dejenerasyonu kaynaklı koroid neovaskülarizasyonunda üçlü tedavi

The triple therapy in choroidal neovascularization due to age related macular degeneration

Pages
187–192
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Triple therapy for SCNM improves visual acuity when used as a primary treatment and stabilizes visual acuity in eyes refractory to prior PDT.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the effectiveness of triple therapy in patients with subfoveal choroidal neovascular membrane (SCNM) due to age-related macular degeneration (AMD) as a primary treatment or as a secondary treatment in patients that were unresponsive to prior photodynamic therapy (PDT).
📊
Key Findings & Data:Materials and Methods: Twenty-nine eyes of 26 patients (10 male, 16 female, mean age: 71.2 years) with SCNM related to AMD were evaluated retrospectively.
💡
Conclusion & Impact:Conclusion: Triple therapy for SCNM improves visual acuity when used as a primary treatment and stabilizes visual acuity in eyes refractory to prior PDT.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Maküler dejenerasyon · Fotokemoterapi · Triamsinolon asetonit

Abstract

Purpose: To evaluate the effectiveness of triple therapy in patients with subfoveal choroidal neovascular membrane (SCNM) due to age-related macular degeneration (AMD) as a primary treatment or as a secondary treatment in patients that were unresponsive to prior photodynamic therapy (PDT). Materials and Methods: Twenty-nine eyes of 26 patients (10 male, 16 female, mean age: 71.2 years) with SCNM related to AMD were evaluated retrospectively. Patients that had no previous PDT constituted Group 1 (17 eyes), and patients that underwent previous PDT constituted Group 2 (12 eyes). Intravitreal injection of 2 mg triamcinolone acetonide combined with 1.25 mg bevacizumab was performed within 10 days period before or after PDT. Results: The mean follow-up was 7.6 months (range, 3-18 months).The average Snellen visual acuity was 0.13±0.02 (± standard error of mean) at the baseline and 0.21±0.03 at the final visit (p=0.02). In Group 1 the mean baseline Snellen visual acuity improved from 0.11±0.03 to 0.26±0.05 at the last visit (p=0.004), whereas in Group 2 the mean visual acuity remained the same (0.16±0.02 versus 0.14±0.02, p=0.46). At the last follow-up, hyperfluorescence on angiography representing the activity of the membrane was evident in 8 eyes (47%) in Group 1, and in 10 eyes (83%) in Group 2. At the final visit, 11 eyes (38%) were leakage-free on fluorescein angiography. Conclusion: Triple therapy for SCNM improves visual acuity when used as a primary treatment and stabilizes visual acuity in eyes refractory to prior PDT.

Özet

Amaç: Yaşa bağlı maküla dejenerasyonu sonucu gelişen subfoveal koroid neovasküler membranlı hastalarda üçlü tedavinin primer tedavi veya fotodinamik tedaviye dirençli vakalarda sekonder tedavi modalitesi olarak etkinliğini değerlendirmek. Gereç ve Yöntemler: Yaşa bağlı maküla dejenerasyonu sonucu subfoveal koroid neovasküler membranı gelişen 26 hastanın 29 gözü (10 erkek ve 16 kadın, ortalama yaş 71.2 yıl) geriye dönük olarak incelendi. Daha önce hiç fotodinamik tedavi yapılmamış hastalar Grup 1 (17 göz) ve daha önce fotodinamik tedavi yapılmış hastalar Grup 2 (12 göz) olarak değerlendirildi. Hastalara fotodinamik tedaviden önce ya da sonra 10 günlük süre içinde intravitreal olarak 2 mg triamsinolon asetonit ile kombine 1.25 mg bevacizumab enjeksiyonu uygulandı. Sonuç: Ortalama takip süresi 7.6 aydı (3-18 arası). Tedavi öncesi ortalama 0.13±0.02 (± SEM) olan Snellen görme keskinliği tedavi sonrası 0.21±0.03’ e yükseldi (p=0.02). Grup 1’ de tedavi öncesi görme keskinliği 0.11±0.03 iken son kontrolde 0.26±0.05 bulundu (p=0.004). Grup 2’de başlangıç (0.16±0.02) ve son görme keskinlikleri (0.14±0.02) fark göstermedi (p=0.46). Grup 1’de 8 gözde (%47), Grup 2’de 10 gözde (%83) tedavi sonrası anjiografide aktif membrana bağlı hiperflorasans izlendi. Son kontrolde toplam 11 (%38) gözde flöresan sızıntısı görülmedi. Tartışma: Subfoveal koroid neovasküler membranlı gözlerde üçlü tedavinin primer uygulaması görme keskinliğini arttırırken, fotodinamik tedaviye dirençli gözlerdeki sekonder uygulaması görme keskinliği stabilizasyonu sağlamaktadır.

🔖

Cite This Article

ÇAKIR, M., ÇEKİÇ, O., ALAGÖZ, C., ALAGÖZ, N., YILMAZ, Ö. F. (2008). Yaşa bağlı makula dejenerasyonu kaynaklı koroid neovaskülarizasyonunda üçlü tedavi. Retina-Vitreus, Cilt: 16 - Sayı: 3, 187–192. https://ajindex.com/articles/308149

References (13)

  1. Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials. TAP report no
  2. Arch Ophthalmol. 2001;119:198-207
  3. Verteporfin in Photodynamic Therapy (VIP) Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization. VIP report no
  4. Am J Ophthalmol. 2001;131:541-560
  5. Spaide RF, Sorenson J, Maranan L.: Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2005;112:301-304
  6. Augustin AJ, Schmidt-Erfurth U.: Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology.2006;113:14-22
  7. Augustin AJ, Schmidt-Erfurth U.: Verteporfin therapy and triamcinolone acetonide: convergent modes of action for treatment of neovascular age-related macular degeneration. Eur J Ophthalmol. 2006;16:824-34
  8. Ergun E, Maar N, Ansari-Shahrezaei S, et al.: Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration. Am J Ophthalmol. 2006;142:10-16
  9. Lazic R, Gabric N.: Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmol. 2007;114:1179-1185
  10. Ahmadieh H, Taei R, Soheilian M, et al.: Single-session photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Eur J Ophthalmol. 2008;18:297-300
  11. Costa RA, Jorge R, Calucci D, et al.: Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Graefes Arch Clin Exp Ophthalmol. 2007;245:1273-1280
  12. Michels S, Schmidt-Erfurth U.: Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci. 2003;44:2147-2154
  13. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, et al.: Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF recept